Two Chinese IPOs Kickstart A Hectic Biotech Fundraising Season
Executive Summary
Two IPOs and 12 venture capital and private equity deals in China raised a combined $1bn in a hectic few weeks of October.
You may also be interested in...
Asia Deal Watch: Nippon Shinyaku Acquires US Rights To Capricor’s DMD Drug
Plus deals involving Aculys/Neurelis, Xtalpi/Excelra, Abbisko/Lilly, Daiichi Sankyo/Cosette, Mitsubishi Tanabe/ADC Therapeutics and PersonGen/Transgene.
China’s Tot Biopharm Secures First Antibody Approval With Avastin Biosimilar
After listing on the Hong Kong stock exchange in late 2019, China’s Tot Biopharm has delivered its first antibody drug approval, with its Pusintin (bevacizumab) biosimilar to Avastin.
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.